Figure 9

Patient derived ovarian cancer cells show similar relationship between bioenergetics phenotype and chemosensitivity. (A) Ratio of OCR: ECAR plotted as a quadrant showing the bioenergetics phenotype of selected patient derived cells. (B) Selected patient derived cells that presented as glycolytic or low metabolic activity (HFOC42, HFOC 49 and HFOC 43) and those that presented as high metabolically active (HFOC 38, HFOC 50 and HFOC 55) were subjected to cisplatin treatment at indicated concentrations and cell survival was determined by Promega Cell Viability Assay at 48 h. Data is presented as percent against control taken as 100% viable. (C) Bar representation of the percent surviving cells compared to respective control cells at 48 h under 25 uM cisplatin exposure. ***p < 0.001, **p < 0.01, cisplatin treated compared to untreated. Abbreviations: OCR: Oxygen Consumption Rate; ECAR: Extracellular Acidification Rate; HFOC: Henry Ford Ovarian Cancer cell line.